Nitrone spin traps and their pyrrolidine analogs in myocardial reperfusion injury : hemodynamic and ESR implications

書誌事項

タイトル別名
  • Evidence for a cardioprotective phosphonate effect for 5‐(diethoxyphosphoryl)‐5‐methyl‐1‐pyrroline <i>N</i>‐oxide in rat hearts

抄録

<jats:p>Formation of free radicals during reperfusion of the isolated ischemic heart has often been demonstrated by detecting hydroxyl radical spin adducts of the nitrone 5,5‐dimethyl‐1‐pyrroline <jats:italic>N</jats:italic>‐oxide (DMPO) in coronary effluents. However, questions still remain regarding (a) whether the reported cardiovascular effects of nitrone perfusion may affect the formation of spin adducts, and (b) the primary generation of superoxide (O.es.cf1.˙.cf5.−.rb.ei2.rb), because of the short persistency of O.es.cf1.˙.cf5.−.rb.ei2.rb/DMPO spin adduct. We therefore compared the effects of perfusing 5 mM of two nitrones, DMPO and 5‐(diethoxyphosphoryl)‐5‐methyl‐1‐pyrroline <jats:italic>N</jats:italic>‐oxide (DEPMPO) or the two structurally related pyrrolidines, diethyl (2‐methyl‐2‐pyrrolidinyl) phosphonate (DEPMPH) and pyrrolidine (PyH), on postischemic functional recovery of rat hearts subjected to 10 min of low‐flow ischemia, 30 min of global ischemia and 60 min of reperfusion. All compounds were added to the perfusate before ischemia, throughout low‐flow ischemia and during the initial 10 min of reflow. In one additional group, hearts received DEPMPO only at reflow. Hemodynamic and <jats:italic>in vitro</jats:italic> ESR evidence is presented indicating that the phosphonate group of DEPMPO and DEPMPH confers these molecules with an enhanced cardioprotective efficacy, unrelated to radical scavenging, acting in synergy with the intrinsic radical trapping effects of the nitronyl group. Continuous‐flow ESR spin trapping using 5.7 mM DEPMPO administered at reflow, but not before ischemia, demonstrated for the first time extended formation of O.es.cf1.˙.cf5.−.rb.ei2.rb in the reperfused myocardium.</jats:p>

収録刊行物

被引用文献 (1)*注記

もっと見る

キーワード

詳細情報

問題の指摘

ページトップへ